Afelimomab

From WikiMD.org
Jump to navigation Jump to search

Afelimomab (pronounced as a-fe-li-mo-mab) is a monoclonal antibody that was designed for the treatment of sepsis. It is a type of biopharmaceutical that was developed by the company Centocor.

Etymology

The name "Afelimomab" is derived from the following components: "Afe" is an arbitrary prefix, "limo" refers to the immune system, "mab" is an abbreviation for monoclonal antibody.

Usage

Afelimomab was used in the treatment of severe sepsis and septic shock, conditions that are characterized by an overwhelming immune response to infection. It works by binding to and neutralizing tumor necrosis factor-alpha (TNF-alpha), a protein that plays a key role in the inflammatory response to infection.

Related Terms

  • Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Sepsis: A life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs.
  • Septic Shock: A severe condition that occurs when an infection leads to life-threatening low blood pressure.
  • Tumor Necrosis Factor-alpha: A cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski